Ligand Pharmaceuticals (LGND) Short term Debt (2011 - 2023)

Ligand Pharmaceuticals (LGND) reported Short term Debt of $76.8 million for Q1 2023, little changed sequentially from $76.7 million in Q4 2022.

Ligand Pharmaceuticals (LGND) Short term Debt (2011 - 2023) Analysis & Trends

Ligand Pharmaceuticals (LGND) has 9 years of Short term Debt data on file, last reported at $76.8 million in Q1 2023.

For the quarter ending Q1 2023, Short term Debt changed N/A year-over-year to $76.8 million; the trailing twelve-month figure through Mar 2023 stood at $76.8 million (changed N/A YoY), and the FY2022 full-year result was $76.7 million, changed N/A from the prior year.
Short term Debt steadied at $76.8 million in Q1 2023, from $76.7 million in the prior quarter.
In the past five years, Short term Debt ranged from a high of $115.0 million in Q2 2022 to a low of $26.8 million in Q1 2019.
A 3-year average of $66.5 million and a median of $76.6 million in 2022 frame the typical range for Short term Debt.
Peak annual rise in Short term Debt reached 87.12% in 2019, while the deepest fall reached 88.24% in 2019.
Tracing LGND's Short term Debt over 3 years: stood at $27.1 million in 2019, then soared by 183.14% to $76.7 million in 2022, then advanced by 0.12% to $76.8 million in 2023.
Business Quant data shows LGND's Short term Debt at $76.8 million in Q1 2023, $76.7 million in Q4 2022, and $76.6 million in Q3 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Ligand Pharmaceuticals	6.05 Bn	5.27 Bn	48.45 Mn

Download Data